Informações:
Falhas:
ID
34861
Descrição
An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence; ODM derived from: https://clinicaltrials.gov/show/NCT02296970
Link
https://clinicaltrials.gov/show/NCT02296970
Palavras-chave
Versões (1)
- 01/02/2019 01/02/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
1 de fevereiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Basal Cell Carcinoma NCT02296970
Eligibility Basal Cell Carcinoma NCT02296970
- StudyEvent: Eligibility
Similar models
Eligibility Basal Cell Carcinoma NCT02296970
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Age | Lesion Very likely Basal cell carcinoma | Lesion Diameter Largest | Location of lesion Trunk | Location of lesion Extremities Proximal Wrist | Location of lesion Extremities Proximal Ankle
Item
patients 18 years or older that are determined by an investigator to have a lesion that is highly likely to be a bcc, less than or equal to 1.0cm in largest diameter, based on clinical examination located in the trunk or extremities, proximal to the wrist and ankles
boolean
C0001779 (UMLS CUI [1])
C0221198 (UMLS CUI [2,1])
C3840799 (UMLS CUI [2,2])
C0007117 (UMLS CUI [2,3])
C0221198 (UMLS CUI [3,1])
C1301886 (UMLS CUI [3,2])
C0443228 (UMLS CUI [3,3])
C2184261 (UMLS CUI [4,1])
C0460005 (UMLS CUI [4,2])
C2184261 (UMLS CUI [5,1])
C0015385 (UMLS CUI [5,2])
C0205107 (UMLS CUI [5,3])
C0043262 (UMLS CUI [5,4])
C2184261 (UMLS CUI [6,1])
C0015385 (UMLS CUI [6,2])
C0205107 (UMLS CUI [6,3])
C0003086 (UMLS CUI [6,4])
C0221198 (UMLS CUI [2,1])
C3840799 (UMLS CUI [2,2])
C0007117 (UMLS CUI [2,3])
C0221198 (UMLS CUI [3,1])
C1301886 (UMLS CUI [3,2])
C0443228 (UMLS CUI [3,3])
C2184261 (UMLS CUI [4,1])
C0460005 (UMLS CUI [4,2])
C2184261 (UMLS CUI [5,1])
C0015385 (UMLS CUI [5,2])
C0205107 (UMLS CUI [5,3])
C0043262 (UMLS CUI [5,4])
C2184261 (UMLS CUI [6,1])
C0015385 (UMLS CUI [6,2])
C0205107 (UMLS CUI [6,3])
C0003086 (UMLS CUI [6,4])
Informed Consent
Item
subject is able to give informed consent
boolean
C0021430 (UMLS CUI [1])
Follow-up Duration Commitment
Item
subject is able to commit to 6 month follow up visit
boolean
C3274571 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0870312 (UMLS CUI [1,3])
C0449238 (UMLS CUI [1,2])
C0870312 (UMLS CUI [1,3])
Basal cell carcinoma Diameter Axis Any
Item
bcc > 1cm in diameter on any one axis.
boolean
C0007117 (UMLS CUI [1,1])
C1301886 (UMLS CUI [1,2])
C1522496 (UMLS CUI [1,3])
C1552551 (UMLS CUI [1,4])
C1301886 (UMLS CUI [1,2])
C1522496 (UMLS CUI [1,3])
C1552551 (UMLS CUI [1,4])
Therapeutic immunosuppression
Item
immunosuppressed patients
boolean
C0021079 (UMLS CUI [1])
Neutropenia
Item
subjects with neutropenia
boolean
C0027947 (UMLS CUI [1])
Organ Transplantation
Item
organ transplant patients
boolean
C0029216 (UMLS CUI [1])
Life Expectancy
Item
subjects with a life expectancy less than year
boolean
C0023671 (UMLS CUI [1])
Immunosuppressive Agents | Prednisone Dosage | Azathioprine | mycophenolate mofetil | Cyclosporine | Tacrolimus Oral Product | TNF-alpha inhibitor | ustekinumab | rituximab
Item
patients taking immunosuppressive medications, including prednisone at a dose of 10mg or greater with an expected duration greater than 4 weeks, azathioprine, mycophenolate mofetil, cyclosporine, oral tacrolimus, any tumor necrosis factor (tnf)-alpha inhibitor, ustekinumab, rituximab, or any other medication in the judgement of the investigator could results in clinically meaningful immunosuppression of the subject
boolean
C0021081 (UMLS CUI [1])
C0032952 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0004482 (UMLS CUI [3])
C0209368 (UMLS CUI [4])
C0010592 (UMLS CUI [5])
C1273163 (UMLS CUI [6])
C1562242 (UMLS CUI [7])
C1608841 (UMLS CUI [8])
C0393022 (UMLS CUI [9])
C0032952 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0004482 (UMLS CUI [3])
C0209368 (UMLS CUI [4])
C0010592 (UMLS CUI [5])
C1273163 (UMLS CUI [6])
C1562242 (UMLS CUI [7])
C1608841 (UMLS CUI [8])
C0393022 (UMLS CUI [9])
Basal cell carcinoma infiltrative Clinical examination | Morpheic basal cell carcinoma Clinical examination
Item
basal cell carcinomas that have infiltrative or morpheaform characteristics based on clinical examination
boolean
C1304298 (UMLS CUI [1,1])
C1456356 (UMLS CUI [1,2])
C0555191 (UMLS CUI [2,1])
C1456356 (UMLS CUI [2,2])
C1456356 (UMLS CUI [1,2])
C0555191 (UMLS CUI [2,1])
C1456356 (UMLS CUI [2,2])
Informed Consent Unable
Item
subjects unable to provide informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,2])
Follow-up Duration Commitment Unable
Item
subjects unable to commit to 6 month follow up
boolean
C3274571 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0870312 (UMLS CUI [1,3])
C1299582 (UMLS CUI [1,4])
C0449238 (UMLS CUI [1,2])
C0870312 (UMLS CUI [1,3])
C1299582 (UMLS CUI [1,4])